Emerge Weight Loss vs K Health
An in-depth comparison of two leading GLP-1 Providers
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
Emerge Weight Loss
Best for patients committed to tirzepatide as their drug of choiceStarting at $299/mo
K Health
Best for users who want general primary care with GLP-1 prescribing as one available option, not a single-condition weight-loss funnelStarting at $300/mo
Side-by-Side Comparison
| Feature | Emerge Weight Loss | K Health |
|---|---|---|
| Overall Score | ✓7.6/10 | 6.6/10 |
| Starting Price | ✓$299/mo | $300/mo |
| Editorial Rating | ✓3.8 ★ /5 | 3.3 ★ /5 |
| Features | 4 features | 4 features |
| States Available | 0 | 0 |
| Compounded | ✓ Yes | — |
| Brand Name | — | ✓ Yes |
| FSA/HSA Accepted | — | — |
| FDA Warnings | None | None |
Pros & Cons
Emerge Weight Loss
Pros
- ✓Tirzepatide-focused (largest effect-size compounded GLP-1)
- ✓Wide dose range available
- ✓Physician-supervised telemedicine model
Cons
- ✗No semaglutide option — limits flexibility if tirzepatide tolerability is poor
- ✗Less brand recognition than Henry Meds, Mochi, or SkinnyRx
K Health
Pros
- ✓Established US telehealth with health-system integrations (Cedars-Sinai, Hartford HealthCare, Hackensack Meridian)
- ✓AI intake reduces upfront friction for users who don't want to sit through a long questionnaire before seeing a clinician
- ✓Primary-care relationship rather than a single-condition funnel — useful for users who want one provider managing multiple conditions
Cons
- ✗Not a GLP-1 specialty platform — weight management is ancillary to primary care, and GLP-1 prescribing is clinician-discretionary at the visit level
- ✗Pricing for GLP-1 specifically is not displayed publicly — needs direct confirmation from K Health support before placing readers
- ✗States served list and pharmacy partners are not publicly enumerated
Our Verdict
Emerge Weight Loss edges out K Health with a higher overall score of 7.6/10 and is particularly strong for patients committed to tirzepatide as their drug of choice. K Health remains a solid alternative, especially if you're looking for users who want general primary care with GLP-1 prescribing as one available option, not a single-condition weight-loss funnel.
Wegovy®, Ozempic®, and Rybelsus® are trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are trademarks of Eli Lilly and Company. All other product names and trademarks referenced on this page belong to their respective owners. WeightLossRankings.org is not affiliated with any pharmaceutical manufacturer. See trademark disclaimer.